Sanjeevani Arora1, Hong Yan2, Iltaeg Cho3, Hua-Ying Fan3, Biao Luo4, Xiaowu Gai5, Dale L Bodian6, Joseph G Vockley6, Yan Zhou7, Elizabeth A Handorf7, Brian L Egleston8, Mark D Andrake9, Emmanuelle Nicolas10, Ilya G Serebriiskii11, Timothy J Yen2, Michael J Hall12, Erica A Golemis13, Greg H Enders14. 1. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 2. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 3. Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Institute for Personalized Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 5. Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts. 6. Inova Translational Medicine Institute, Inova Health System, Falls Church, Virginia. 7. Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 8. Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 9. Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 10. Genomics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 11. Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Kazan Federal University, Kazan, Russia. 12. Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 13. Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: erica.golemis@fccc.edu. 14. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: greg.enders@fccc.edu.
Abstract
BACKGROUND & AIMS: DNA structural lesions are prevalent in sporadic colorectal cancer. Therefore, we proposed that gene variants that predispose to DNA double-strand breaks (DSBs) would be found in patients with familial colorectal carcinomas of an undefined genetic basis (UFCRC). METHODS: We collected primary T cells from 25 patients with UFCRC and matched patients without colorectal cancer (controls) and assayed for DSBs. We performed exome sequence analyses of germline DNA from 20 patients with UFCRC and 5 undiagnosed patients with polyposis. The prevalence of identified variants in genes linked to DNA integrity was compared with that of individuals without a family history of cancer. The effects of representative variants found to be associated with UFCRC was confirmed in functional assays with HCT116 cells. RESULTS: Primary T cells from most patients with UFCRC had increased levels of the DSB marker γ(phosphorylated)histone2AX (γH2AX) after treatment with DNA damaging agents, compared with T cells from controls (P < .001). Exome sequence analysis identified a mean 1.4 rare variants per patient that were predicted to disrupt functions of genes relevant to DSBs. Controls (from public databases) had a much lower frequency of variants in the same genes (P < .001). Knockdown of representative variant genes in HCT116 CRC cells increased γH2AX. A detailed analysis of immortalized patient-derived B cells that contained variants in the Werner syndrome, RecQ helicase-like gene (WRN, encoding T705I), and excision repair cross-complementation group 6 (ERCC6, encoding N180Y) showed reduced levels of these proteins and increased DSBs, compared with B cells from controls. This phenotype was rescued by exogenous expression of WRN or ERCC6. Direct analysis of the recombinant variant proteins confirmed defective enzymatic activities. CONCLUSIONS: These results provide evidence that defects in suppression of DSBs underlie some cases of UFCRC; these can be identified by assays of circulating lymphocytes. We specifically associated UFCRC with variants in WRN and ERCC6 that reduce the capacity for repair of DNA DSBs. These observations could lead to a simple screening strategy for UFCRC, and provide insight into the pathogenic mechanisms of colorectal carcinogenesis.
BACKGROUND & AIMS: DNA structural lesions are prevalent in sporadic colorectal cancer. Therefore, we proposed that gene variants that predispose to DNA double-strand breaks (DSBs) would be found in patients with familial colorectal carcinomas of an undefined genetic basis (UFCRC). METHODS: We collected primary T cells from 25 patients with UFCRC and matched patients without colorectal cancer (controls) and assayed for DSBs. We performed exome sequence analyses of germline DNA from 20 patients with UFCRC and 5 undiagnosed patients with polyposis. The prevalence of identified variants in genes linked to DNA integrity was compared with that of individuals without a family history of cancer. The effects of representative variants found to be associated with UFCRC was confirmed in functional assays with HCT116 cells. RESULTS: Primary T cells from most patients with UFCRC had increased levels of the DSB marker γ(phosphorylated)histone2AX (γH2AX) after treatment with DNA damaging agents, compared with T cells from controls (P < .001). Exome sequence analysis identified a mean 1.4 rare variants per patient that were predicted to disrupt functions of genes relevant to DSBs. Controls (from public databases) had a much lower frequency of variants in the same genes (P < .001). Knockdown of representative variant genes in HCT116 CRC cells increased γH2AX. A detailed analysis of immortalized patient-derived B cells that contained variants in the Werner syndrome, RecQ helicase-like gene (WRN, encoding T705I), and excision repair cross-complementation group 6 (ERCC6, encoding N180Y) showed reduced levels of these proteins and increased DSBs, compared with B cells from controls. This phenotype was rescued by exogenous expression of WRN or ERCC6. Direct analysis of the recombinant variant proteins confirmed defective enzymatic activities. CONCLUSIONS: These results provide evidence that defects in suppression of DSBs underlie some cases of UFCRC; these can be identified by assays of circulating lymphocytes. We specifically associated UFCRC with variants in WRN and ERCC6 that reduce the capacity for repair of DNA DSBs. These observations could lead to a simple screening strategy for UFCRC, and provide insight into the pathogenic mechanisms of colorectal carcinogenesis.
Authors: Randall W Burt; Jamie A Cannon; Donald S David; Dayna S Early; James M Ford; Francis M Giardiello; Amy L Halverson; Stanley R Hamilton; Heather Hampel; Mohammad K Ismail; Kory Jasperson; Jason B Klapman; Audrey J Lazenby; Patrick M Lynch; Robert J Mayer; Reid M Ness; Dawn Provenzale; M Sambasiva Rao; Moshe Shike; Gideon Steinbach; Jonathan P Terdiman; David Weinberg; Mary Dwyer; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2013-12-01 Impact factor: 11.908
Authors: Lorenzo Costantino; Sotirios K Sotiriou; Juha K Rantala; Simon Magin; Emil Mladenov; Thomas Helleday; James E Haber; George Iliakis; Olli P Kallioniemi; Thanos D Halazonetis Journal: Science Date: 2013-12-05 Impact factor: 47.728
Authors: Nuria Seguí; Leonardo B Mina; Conxi Lázaro; Rebeca Sanz-Pamplona; Tirso Pons; Matilde Navarro; Fernando Bellido; Adriana López-Doriga; Rafael Valdés-Mas; Marta Pineda; Elisabet Guinó; August Vidal; José Luís Soto; Trinidad Caldés; Mercedes Durán; Miguel Urioste; Daniel Rueda; Joan Brunet; Milagros Balbín; Pilar Blay; Silvia Iglesias; Pilar Garré; Enrique Lastra; Ana Beatriz Sánchez-Heras; Alfonso Valencia; Victor Moreno; Miguel Ángel Pujana; Alberto Villanueva; Ignacio Blanco; Gabriel Capellá; Jordi Surrallés; Xose S Puente; Laura Valle Journal: Gastroenterology Date: 2015-06-05 Impact factor: 22.682
Authors: Ulrike Peters; Shuo Jiao; Fredrick R Schumacher; Carolyn M Hutter; Aaron K Aragaki; John A Baron; Sonja I Berndt; Stéphane Bézieau; Hermann Brenner; Katja Butterbach; Bette J Caan; Peter T Campbell; Christopher S Carlson; Graham Casey; Andrew T Chan; Jenny Chang-Claude; Stephen J Chanock; Lin S Chen; Gerhard A Coetzee; Simon G Coetzee; David V Conti; Keith R Curtis; David Duggan; Todd Edwards; Charles S Fuchs; Steven Gallinger; Edward L Giovannucci; Stephanie M Gogarten; Stephen B Gruber; Robert W Haile; Tabitha A Harrison; Richard B Hayes; Brian E Henderson; Michael Hoffmeister; John L Hopper; Thomas J Hudson; David J Hunter; Rebecca D Jackson; Sun Ha Jee; Mark A Jenkins; Wei-Hua Jia; Laurence N Kolonel; Charles Kooperberg; Sébastien Küry; Andrea Z Lacroix; Cathy C Laurie; Cecelia A Laurie; Loic Le Marchand; Mathieu Lemire; David Levine; Noralane M Lindor; Yan Liu; Jing Ma; Karen W Makar; Keitaro Matsuo; Polly A Newcomb; John D Potter; Ross L Prentice; Conghui Qu; Thomas Rohan; Stephanie A Rosse; Robert E Schoen; Daniela Seminara; Martha Shrubsole; Xiao-Ou Shu; Martha L Slattery; Darin Taverna; Stephen N Thibodeau; Cornelia M Ulrich; Emily White; Yongbing Xiang; Brent W Zanke; Yi-Xin Zeng; Ben Zhang; Wei Zheng; Li Hsu Journal: Gastroenterology Date: 2012-12-22 Impact factor: 22.682
Authors: Claire Palles; Jean-Baptiste Cazier; Kimberley M Howarth; Enric Domingo; Angela M Jones; Peter Broderick; Zoe Kemp; Sarah L Spain; Estrella Guarino; Estrella Guarino Almeida; Israel Salguero; Amy Sherborne; Daniel Chubb; Luis G Carvajal-Carmona; Yusanne Ma; Kulvinder Kaur; Sara Dobbins; Ella Barclay; Maggie Gorman; Lynn Martin; Michal B Kovac; Sean Humphray; Anneke Lucassen; Christopher C Holmes; David Bentley; Peter Donnelly; Jenny Taylor; Christos Petridis; Rebecca Roylance; Elinor J Sawyer; David J Kerr; Susan Clark; Jonathan Grimes; Stephen E Kearsey; Huw J W Thomas; Gilean McVean; Richard S Houlston; Ian Tomlinson Journal: Nat Genet Date: 2012-12-23 Impact factor: 38.330
Authors: Dale L Bodian; Justine N McCutcheon; Prachi Kothiyal; Kathi C Huddleston; Ramaswamy K Iyer; Joseph G Vockley; John E Niederhuber Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240
Authors: Sanjeevani Arora; Peter J Huwe; Rahmat Sikder; Manali Shah; Amanda J Browne; Randy Lesh; Emmanuelle Nicolas; Sanat Deshpande; Michael J Hall; Roland L Dunbrack; Erica A Golemis Journal: Cancer Biol Ther Date: 2017-05-11 Impact factor: 4.742
Authors: Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins Journal: Genes Dev Date: 2018-06-26 Impact factor: 11.361
Authors: Rosa M Xicola; Julia R Clark; Timothy Carroll; Jurgis Alvikas; Priti Marwaha; Maureen R Regan; Francesc Lopez-Giraldez; Jungmin Choi; Rajyasree Emmadi; Victoria Alagiozian-Angelova; Sonia S Kupfer; Nathan A Ellis; Xavier Llor Journal: Fam Cancer Date: 2019-07 Impact factor: 2.375
Authors: Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: Shreya M Shah; Elena V Demidova; Randy W Lesh; Michael J Hall; Mary B Daly; Joshua E Meyer; Martin J Edelman; Sanjeevani Arora Journal: Cancer Treat Rev Date: 2022-01-05 Impact factor: 13.608
Authors: Sara E Dobbins; Peter Broderick; Daniel Chubb; Ben Kinnersley; Amy L Sherborne; Richard S Houlston Journal: Fam Cancer Date: 2016-10 Impact factor: 2.375